Interaction between domperidone and ketoconazole: Toward prediction of consequent QTc prolongation using purely in vitro information

CPT: Pharmacometrics and Systems Pharmacology

Volumn 3, Issue 8, 2014, Pages

  Mishra, H ^a   Polak, S ^a,b   Jamei, M ^a   Rostami Hodjegan, A ^a,c  

^a CERTARA UK LIMITED   (United Kingdom)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84906859136     PISSN: None     EISSN: 21638306     Source Type: Journal    
DOI: 10.1038/psp.2014.26     Document Type: Article

References (51)

1. Piccini, J.P. et al.; CSRC/HESI Writing Group. Current challenges in the evaluation of cardiac safety during drug development: translational medicine meets the Critical Path Initiative. Am. Heart J. 158, 317-326 (2009).
2. International Conference on Harmonisation. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrythmic drugs. http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/ Efficacy/E14/E14-Guideline.pdf. Accessed 01 March 2005.
3. Piotrovsky, V. Pharmacokinetic-pharmacodynamic modeling in the data analysis and interpretation of drug-induced QT/QTc prolongation. AAPS J. 7, E609-E624 (2005).
4. Brennan, T., Fink, M. & Rodriguez, B. Multiscale modelling of drug-induced effects on cardiac electrophysiological activity. Eur. J. Pharm. Sci. 36, 62-77 (2009).
5. Towart, R. et al. Blockade of the I(Ks) potassium channel: An overlooked cardiovascular liability in drug safety screening? J. Pharmacol. Toxicol. Methods 60, 1-10 (2009).
6. Fenichel, R.R. et al.; Independent Academic Task Force. Drug-induced torsades de pointes and implications for drug development. J. Cardiovasc. Electrophysiol. 15, 475-495 (2004).
7. Noble, D. Modeling the heart-from genes to cells to the whole organ. Science 295, 1678-1682 (2002).
8. Mirams, G.R. et al. Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk. Cardiovasc. Res. 91, 53-61 (2011).
9. Zemzemi, N. et al. Computational assessment of drug-induced effects on the electrocardiogram: from ion channel to body surface potentials. Br. J. Pharmacol. 168, 718-733 (2013).
10. Polak, S. In vitro to human in vivo translation - pharmacokinetics and pharmacodynamics of quinidine. ALTEX 30, 309-318 (2013).
11. Heykants, J., Hendriks, R., Meuldermans, W., Michiels, M., Scheygrond, H. & Reyntjens, H. On the pharmacokinetics of domperidone in animals and man. IV. The pharmacokinetics of intravenous domperidone and its bioavailability in man following intramuscular, oral and rectal administration. Eur. J. Drug Metab. Pharmacokinet. 6, 61-70 (1981).
12. Zhang, C.H. et al. A novel domperidone hydrogel: preparation, characterization, pharmacokinetic, and pharmacodynamic properties. J. Drug Deliv. 2011, 841054 (2011).
13. De Buck, S.S., Sinha, V.K., Fenu, L.A., Nijsen, M.J., Mackie, C.E. & Gilissen, R.A. Prediction of human pharmacokinetics using physiologically based modeling: a retrospective analysis of 26 clinically tested drugs. Drug Metab. Dispos. 35, 1766-1780 (2007).
14. Ward, B.A., Morocho, A., Kandil, A., Galinsky, R.E., Flockhart, D.A. & Desta, Z. Characterization of human cytochrome P450 enzymes catalyzing domperidone N-dealkylation and hydroxylation in vitro. Br. J. Clin. Pharmacol. 58, 277-287 (2004).
15. Boyce, M.J., Baisley, K.J. & Warrington, S.J. Pharmacokinetic interaction between domperidone and ketoconazole leads to QT prolongation in healthy volunteers: a randomized, placebo-controlled, double-blind, crossover study. Br. J. Clin. Pharmacol. 73, 411-421 (2012).
16. Drolet, B., Rousseau, G., Daleau, P., Cardinal, R. & Turgeon, J. Domperidone should not be considered a no-risk alternative to cisapride in the treatment of gastrointestinal motility disorders. Circulation 102, 1883-1885 (2000).
17. Claassen, S. & Zünkler, B.J. Comparison of the effects of metoclopramide and domperidone on HERG channels. Pharmacology 74, 31-36 (2005).
18. Medicines Control Council. Interaction between ketoconazole and domperidone and the risk of QT prolongation-important safety information. S Afr Med J. 96, 596 (2006).
19. National Center for Biotechnology Information. Domperidone - Compound Summary. PubChem Compound Database. http://pubchem.ncbi.nlm.nih.gov/summary/ summary.cgi?cid=3151. Accessed 04 January 2012.
20. Faassen, F., Vogel, G., Spanings, H. & Vromans, H. Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int. J. Pharm. 263, 113-122 (2003).
21. Huang, Y.C., Colaizzi, J.L., Bierman, R.H., Woestenborghs, R. & Heykants, J.J. Pharmacokinetics and dose proportionality of domperidone in healthy volunteers. J. Clin. Pharmacol. 26, 628-632 (1986).
22. Clayton, R. & Booker, E. A Guide for IVIVE and PBPK/PD Modelling using the Simcyp Population-based Simulator. Version 12. (Simcyp Ltd (a Certara Company), Sheffield, 2012).
23. Kuryshev, Y.A., Bruening-Wright, A., Brown, A.M. & Kirsch, G.E. Increased cardiac risk in concomitant methadone and diazepam treatment: pharmacodynamic interactions in cardiac ion channels. J. Cardiovasc. Pharmacol. 56, 420-430 (2010).
24. Hreiche, R., Plante, I., Drolet, B., Morissette, P. & Turgeon, J. Lengthening of cardiac repolarization in isolated guinea pigs hearts by sequential or concomitant administration of two IKr blockers. J. Pharm. Sci. 100, 2469-2481 (2011).
25. Champeroux, P. et al. A step towards characterisation of electrophysiological profile of torsadogenic drugs. J. Pharmacol. Toxicol. Methods 63, 269-278 (2011).
26. Lacerda, A.E., Kramer, J., Shen, K.Z., Thomas, D. & Brown, A.M. Comparison of block among cloned cardiac potassium channels by non-antiarrhythmic drugs. Eur Heart J Suppl. 3, K23-K30 (2001).
27. Kramer, J. et al. MICE models: superior to the HERG model in predicting Torsade de Pointes. Sci. Rep. 3, 2100 (2013).
28. Cieniawa, J., Baszak, J., Olchowik, G. & Widomska, J. Modeling gender effects on electrical activity of single ventricular myocytes. Comput. Biol. Med. 43, 1063-1072 (2013).
29. Polak, S., Wisniowska, B., Fijorek, K., Glinka, A. & Mendyk, A. In vitro-in vivo extrapolation of drug-induced proarrhythmia predictions at the population level. Drug Discov. Today 19, 275-281 (2014).
30. Sheiner, L.B. Learning versus confirming in clinical drug development. Clin. Pharmacol. Ther. 61, 275-291 (1997).
31. Djelouah, I. Heart rate and rhythm disorders. Canadian Adverse Reaction Newsletter 17, 2 (2007).
32. Michaud, V. & Turgeon, J. Domperidone and sudden cardiac death: How much longer should we wait? J. Cardiovasc. Pharmacol. 61, 215-217 (2013).
33. Digby, G.C. et al. Acquired long QT interval: a case series of multifactorial QT prolongation. Clin. Cardiol. 34, 577-582 (2011).
34. Hondeghem, L.M. Domperidone: limited benefits with significant risk for sudden cardiac death. J. Cardiovasc. Pharmacol. 61, 218-225 (2013).
35. http://www.ema.europa.eu/docs/en-GB/document-library/Referrals-document/ Domperidone-31/Procedure-started/WC500139769.pdf.
36. Glinka, A. & Polak, S. The effects of six antipsychotic agents on QTc-an attempt to mimic clinical trial through simulation including variability in the population. Comput. Biol. Med. 47, 20-26 (2014).
37. The DrugBank Database. DrugBank: Domperidone (DB01184). http://www.drugbank.ca/drugs/DB01184. Accessed 04 January 2012.
38. Berezhkovskiy, L.M. Volume of distribution at steady state for a linear pharmacokinetic system with peripheral elimination. J. Pharm. Sci. 93, 1628-1640 (2004).
39. Jamei, M., Marciniak, S., Feng, K., Barnett, A., Tucker, G. & Rostami-Hodjegan, A. The Simcyp population-based ADME simulator. Expert Opin. Drug Metab. Toxicol. 5, 211-223 (2009).
40. Poulin, P. & Theil, F.P. Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution. J. Pharm. Sci. 91, 129-156 (2002).
41. Poulin, P. & Theil, F.P. Prediction of pharmacokinetics prior to in vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition. J. Pharm. Sci. 91, 1358-1370 (2002).
42. Chang, S.Y., Fancher, R.M., Zhang, H. & Gan, J. Mechanism-based inhibition of human cytochrome P4503A4 by domperidone. Xenobiotica. 40, 138-145 (2010).
43. Daneshmend, T.K., Warnock, D.W., Turner, A. & Roberts, C.J. Pharmacokinetics of ketoconazole in normal subjects. J. Antimicrob. Chemother. 8, 299-304 (1981).
44. Kobylinska, M. & Kobylinska, K. High-performance liquid chromatographic analysis for the determination of domperidone in human plasma. J. Chromatogr. B Biomed. Sci. Appl. 744, 207-212 (2000).
45. Polak, S. Tox-Portal.Net. http://www.tox-portal.net/index.html. Accessed 02 February 2012.
46. Polak, S., Fijorek, K., Glinka, A., Wisniowska, B. & Mendyk, A. Virtual population generator for human cardiomyocytes parameters: in silico drug cardiotoxicity assessment. Toxicol. Mech. Methods 22, 31-40 (2012).
47. Ridley, J.M. et al. Inhibition of the HERG K+ channel by the antifungal drug ketoconazole depends on channel gating and involves the S6 residue F656. FEBS Lett. 580, 1999-2005 (2006).
48. Polak, S., Wisniowska, B., Glinka, A., Fijorek, K. & Mendyk, A. Slow delayed rectifying potassium current (IKs) - analysis of the in vitro inhibition data and predictive model development. J. Appl. Toxicol. 33, 723-739 (2013).
49. Polak, S. & Fijorek, K. Inter-individual variability in the pre-clinical drug cardiotoxic safety assessment-analysis of the age-cardiomyocytes electric capacitance dependence. J. Cardiovasc. Transl. Res. 5, 321-332 (2012).
50. Fijorek, K., Patel, N., Klima, L., Stolarz-Skrzypek, K., Kawecka-Jaszcz, K. & Polak, S. Age and gender dependent heart rate circadian model development and performance verification on the proarrhythmic drug case study. Theor. Biol. Med. Model. 10, 7 (2013).
51. Fijorek, K., Puskulluoglu, M. & Polak, S. Circadian models of serum potassium, sodium, and calcium concentrations in healthy individuals and their application to cardiac electrophysiology simulations at individual level. Comput. Math. Methods Med. 2013, 429037 (2013).